BriaCell Therapeutics Corp. (BCTXW) Financial Statements (2026 and earlier)
Company Profile
| Business Address |
3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER, BC V7T 2X1 |
| State of Incorp. | BC |
| Fiscal Year End | July 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) (USD)
| 10/31/2025 MRQ | 7/31/2025 | 1/31/2025 MRQ | 7/31/2024 | 7/31/2023 | 7/31/2022 | |||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash, cash equivalents, and short-term investments | 17,866,281 | 5,013,654 | 862,089 | 21,251,092 | 41,041,652 | |||
| Cash and cash equivalent | 10,493,808 | 5,013,654 | 862,089 | 21,251,092 | 41,041,652 | |||
| Short-term investments | 7,372,473 | |||||||
| Receivables | 18,873 | 24,103 | ||||||
| Prepaid expense | 1,394,439 | 1,322,122 | 5,678,542 | 1,280,945 | ||||
| Other undisclosed current assets | 665,856 | 2,148,919 | 1,469,643 | |||||
| Total current assets: | 19,926,576 | 7,162,573 | 3,653,854 | 26,948,507 | 42,346,700 | |||
| Noncurrent Assets | ||||||||
| Property, plant and equipment | 296,819 | 342,497 | 388,175 | |||||
| Long-term investments and receivables | 524,278 | 454,391 | 418,490 | 2 | 2 | |||
| Long-term investments | 524,278 | 454,391 | 418,490 | 2 | 2 | |||
| Intangible assets, net (including goodwill) | 184,525 | 192,160 | 199,796 | 215,068 | 230,339 | |||
| Intangible assets, net (excluding goodwill) | 184,525 | 192,160 | 199,796 | 215,068 | 230,339 | |||
| Prepaid expense | 717,508 | 1,211,946 | 1,211,946 | |||||
| Total noncurrent assets: | 1,723,130 | 2,200,994 | 2,218,407 | 215,070 | 230,341 | |||
| TOTAL ASSETS: | 21,649,706 | 9,363,567 | 5,872,261 | 27,163,577 | 42,577,041 | |||
| LIABILITIES AND EQUITY | ||||||||
| Liabilities | ||||||||
| Current Liabilities | ||||||||
| Accounts payable and accrued liabilities | 3,283,703 | 5,003,239 | 7,170,781 | 1,781,457 | 871,367 | |||
| Accounts payable | 3,283,703 | 5,003,239 | 7,170,781 | 1,123,739 | 463,280 | |||
| Accrued liabilities | 657,718 | 408,087 | ||||||
| Other undisclosed current liabilities | 694,285 | 227,599 | 290,376 | 20,000 | 69,720 | |||
| Total current liabilities: | 3,977,988 | 5,230,838 | 7,461,157 | 1,801,457 | 941,087 | |||
| Noncurrent Liabilities | ||||||||
| Liabilities, other than long-term debt | 337,672 | 905,838 | 1,096,036 | |||||
| Derivative instruments and hedges, liabilities | 337,672 | 905,838 | 1,096,036 | |||||
| Other undisclosed noncurrent liabilities | 29,139,301 | 31,307,022 | ||||||
| Total noncurrent liabilities: | 337,672 | 905,838 | 1,096,036 | 29,139,301 | 31,307,022 | |||
| Total liabilities: | 4,315,660 | 6,136,676 | 8,557,193 | 30,940,758 | 32,248,109 | |||
| Equity | ||||||||
| Equity, attributable to parent, including: | (10,154,325) | (12,224,857) | (13,415,967) | (3,777,181) | 10,328,932 | |||
| Common stock | 101,739,923 | 85,451,119 | 72,166,414 | 69,591,784 | 65,589,293 | |||
| Additional paid in capital | 5,228,160 | |||||||
| Accumulated other comprehensive loss | (138,684) | (138,684) | (138,684) | (138,684) | (138,684) | |||
| Accumulated deficit | (111,755,564) | (97,537,292) | (85,443,697) | (80,652,231) | (60,349,837) | |||
| Other undisclosed equity, attributable to parent | 7,421,950 | |||||||
| Equity, attributable to noncontrolling interest | (546,795) | (376,031) | (302,522) | |||||
| Other undisclosed equity | 28,035,166 | 15,827,779 | 11,033,557 | |||||
| Total equity: | 17,334,046 | 3,226,891 | (2,684,932) | (3,777,181) | 10,328,932 | |||
| TOTAL LIABILITIES AND EQUITY: | 21,649,706 | 9,363,567 | 5,872,261 | 27,163,577 | 42,577,041 | |||
Income Statement (P&L) (USD)
| 10/31/2025 TTM | 7/31/2025 | 1/31/2025 TTM | 7/31/2024 | 7/31/2023 | 7/31/2022 | ||
|---|---|---|---|---|---|---|---|
| Operating expenses | (27,204,803) | (27,319,877) | (33,330,076) | (23,272,264) | (15,288,941) | ||
| Operating loss: | (27,204,803) | (27,319,877) | (33,330,076) | (23,272,264) | (15,288,941) | ||
| Nonoperating income (expense) | 114,511 | (12,634,143) | 262,566 | 2,969,870 | (11,549,962) | ||
| Investment income, nonoperating | 119,958 | 75,488 | 288,018 | 891,213 | 136,731 | ||
| Gain (loss), foreign currency transaction, before tax | (24,941) | 16,799 | (25,452) | (40,873) | |||
| Interest and debt expense | (36,979) | (979) | |||||
| Loss from continuing operations before equity method investments, income taxes: | (27,127,271) | (39,954,020) | (33,067,510) | (20,302,394) | (26,839,882) | ||
| Loss from equity method investments | (224,212) | (202,264) | (106,510) | ||||
| Other undisclosed income from continuing operations before income taxes | 53,907,623 | 38,105,568 | 38,105,568 | 979 | |||
| Income (loss) from continuing operations: | 26,556,140 | (2,050,716) | 4,931,548 | (20,302,394) | (26,838,903) | ||
| Loss before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | ✕ | ✕ | (26,838,903) | |
| Other undisclosed net loss | (53,112,280) | (9,672,898) | (9,863,096) | ||||
| Net loss: | (26,556,140) | (11,723,614) | (4,931,548) | (20,302,394) | (26,838,903) | ||
| Net income attributable to noncontrolling interest | 244,273 | 131,613 | 140,082 | ||||
| Net loss attributable to parent: | (26,311,867) | (11,592,001) | (4,791,466) | (20,302,394) | (26,838,903) | ||
| Other undisclosed net loss available to common stockholders, basic | (140,082) | (140,082) | |||||
| Net loss available to common stockholders, diluted: | (26,311,867) | (11,732,083) | (4,931,548) | (20,302,394) | (26,838,903) | ||
Comprehensive Income (USD)
| 10/31/2025 TTM | 7/31/2025 | 1/31/2025 TTM | 7/31/2024 | 7/31/2023 | 7/31/2022 | ||
|---|---|---|---|---|---|---|---|
| Net loss: | (26,556,140) | (11,723,614) | (4,931,548) | (20,302,394) | (26,838,903) | ||
| Comprehensive loss: | (26,556,140) | (11,723,614) | (4,931,548) | (20,302,394) | (26,838,903) | ||
| Comprehensive income, net of tax, attributable to noncontrolling interest | 244,273 | 131,613 | 140,082 | ||||
| Comprehensive loss, net of tax, attributable to parent: | (26,311,867) | (11,592,001) | (4,791,466) | (20,302,394) | (26,838,903) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.